Get the Stockscreener App
0.6682
1.24%
0.0082
Scynexis Inc stock is traded at $0.6682, with a volume of 133.83K.
It is up +1.24% in the last 24 hours and up +6.05% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.66
Open:
$0.65
24h Volume:
133.83K
Relative Volume:
0.25
Market Cap:
$28.04M
Revenue:
$3.26M
Net Income/Loss:
$-19.52M
P/E Ratio:
-1.6705
EPS:
-0.4
Net Cash Flow:
$-24.10M
1W Performance:
-1.47%
1M Performance:
+6.05%
6M Performance:
-28.84%
1Y Performance:
-47.39%
1-Day Range:
$0.65
$0.67
1-Week Range:
$0.65
$0.7197
52-Week Range:
$0.565
$1.49
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.6682 | 27.70M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
120.41 | 54.02B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.28 | 45.21B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.53 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.41 | 31.93B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
485.21 | 20.71B | 3.08B | 1.24B | 1.07B | 25.61 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
Why SCYNEXIS Inc. (135A) stock stays resilientWeekly Stock Report & Smart Swing Trading Techniques - Newser
How SCYNEXIS Inc. stock trades before earnings2025 Breakouts & Breakdowns & Low Drawdown Momentum Ideas - Newser
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
What is the fair value of SCYNEXIS Inc. stock nowEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is SCYNEXIS Inc. (135A) stock considered safe havenDollar Strength & Low Risk Investment Opportunities - Newser
Can SCYNEXIS Inc. stock surprise with earnings upsideJuly 2025 Reactions & Accurate Buy Signal Alerts - Newser
Free cash flow per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
Working capital per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
Macro Review: Why SCYNEXIS Inc. stock is trending among retail tradersJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - BỘ NỘI VỤ
Why SCYNEXIS Inc. stock is a must watch in 2025Portfolio Gains Report & Community Verified Swing Trade Signals - moha.gov.vn
Why SCYNEXIS Inc. (135A) stock is listed among top recommendationsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - BỘ NỘI VỤ
Is SCYNEXIS Inc a good long term investmentGrowth Stock Opportunities & Exceptional Return Growth - earlytimes.in
Is SCYNEXIS Inc. stock trading at a premium valuation2025 Short Interest & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
It is Poised to be a Bull Market for Scynexis Inc (SCYX) - Setenews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Investors in cash trouble should check out Scynexis Inc (SCYX) - Setenews
Will SCYNEXIS Inc. (135A) stock outperform foreign stocksJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration - MSN
Analyzing recovery setups for SCYNEXIS Inc. investorsFed Meeting & Fast Gain Stock Trading Tips - newser.com
Will SCYNEXIS Inc. stock recover faster than peersJuly 2025 Update & Technical Pattern Alert System - newser.com
Scynexis Transfers Brexafemme New Drug Application to GSK - MarketScreener
SCYNEXIS, Inc. Completes Transfer of Brexafungerp New Drug Application to Gsk - MarketScreener
Scynexis completes transfer of Brexafemme new drug application to GSK - MarketScreener
SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties - Quiver Quantitative
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - The Manila Times
Scynexis completes transfer of Brexafemme New Drug Application To GSK - TradingView
SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan
Is SCYNEXIS Inc. stock attractive for passive investorsMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
How to build a dashboard for SCYNEXIS Inc. stockEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Scynexis fungerps among funding recipients - BioWorld MedTech
SCYNEXIS receives $7 million annual grant for antifungal research By Investing.com - Investing.com Nigeria
SCYX Secures Federal Grant for Antifungal Research - GuruFocus
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections - The Manila Times
SCYNEXIS Receives $35 Million NIH Grant to Develop Next-Generation Antifungal Therapies - Quiver Quantitative
Scynexis (NASDAQ: SCYX) fungerps program included in $7M NIH CETR grant - Stock Titan
Why SCYNEXIS Inc. (135A) stock benefits from AI revolutionForecast Cut & AI Forecast Swing Trade Picks - newser.com
Live market analysis of SCYNEXIS Inc.July 2025 Recap & Community Verified Trade Signals - newser.com
Will SCYNEXIS Inc. (135A) stock deliver stable dividendsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
How geopolitical tensions affect SCYNEXIS Inc. stockEarnings Recap Summary & Consistent Return Investment Signals - newser.com
SCYX | SCYNEXIS Inc. SEC Filings - MarketWatch
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.96%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):